Search NEL Online

Case Reports 2013; 34(6): 504-507 PubMed PMID: 24378455 Citation  Keywords:  Aged, Aluminum:blood, Alzheimer Disease:drug therapy, Antioxidants:therapeutic use, Ascorbic Acid:therapeutic use, Chelation Therapy:methods, Deferoxamine:therapeutic use, Epilepsy:drug therapy, Fatal Outcome, Female, Humans, Iron:blood, Siderophores:ther.   

: In this case presentation, a woman with high serum levels of aluminum was treated with chelation therapy with deferoxamine and ascorbic acid. This patient was initially bedridden and the clinical situation was complicated by epileptic seizures. After the chelation therapy, the clinical condition was ameliorated and the therapy continued without the correlation to aluminum serum levels. The role of metals in neurodegenerative disorders and the correlation between iron metabolism and amyloid beta peptide are described. This case suggests chelation therapy could represent a promising therapeutic option for this dramatic disease....

Read abstract  Full text PDF

Case Reports 2012; 33(3): 249-256 PubMed PMID: 22635078 Citation  Keywords:  Antineoplastic Agents, Alkylating:therapeutic use, Antineoplastic Agents, Hormonal:therapeutic use, Antioxidants:therapeutic use, Calcium:therapeutic use, Carcinoma, Medullary:drug therapy, Carcinoma, Squamous Cell:drug therapy, Chondroitin Sulfates:thera.   

: In 23 cases of carcinoma of the head and neck, the combined use of Somatostatin and/or its analogue Octreotide, prolactin inhibitors, Melatonin, Retinoids, Vitamin E, Vitamin D3, Vitamin C, Calcium, chondroitin-sulphate, and minimal oral doses of cyclophosphamide (50-100 mg/day) led to a decided increase in survival with respect to the median values reported in the literature for the same tumours and stages, together with an evident improvement in the quality of life, partial or complete objective responses and, in some cases, complete and stable cure with functional recovery. The rationale and the mechanisms of molecular biology of the treatment are discussed, showing that the treatment has a differentiating, apoptotic, antiproliferative, antiangiogenic and antimetastatic effect, and, unlike chemo- and/or radiotherapy, preserves and enhances the trophism and functionality of organs, tissues and immunitary and antitumoral homeostasis. This result, achieved without toxicity, demonstrates the efficacy of this biological multitherapy (Prof. Luigi Di Bella's method or DBM) and is in agreement with the positive results already published on the use of the DBM in various neoplastic diseases. We believe it is of use to report these cases to invite greater interest in the possibilities opened up by this biological multitherapy....

Read abstract  Full text PDF

Journal Article 2011; 32(5): 575-587 PubMed PMID: 22167140 Citation  Keywords:  Animals, Antioxidants:therapeutic use, Drug Industry:methods, Endocrine System Diseases:drug therapy, Humans, Melatonin:therapeutic use, Phytotherapy:methods, Reproduction:drug effects,.   

: Novel functions of melatonin continue to be uncovered. Those summarized in this report include actions at the level of the peripheral reproductive organs and include functions as an antioxidant to protect the maturing oocyte in the vesicular follicle and during ovulation, melatonin actions on the developing fetus particularly in relation to organizing the circadian system, its potential utility in combating the consequences of pre-eclampsia, reducing intrauterine growth restriction, suppressing endometriotic growths and improving the outcomes of in vitro fertilization/embryo transfer. The inhibitory effects of melatonin on many cancer types have been known for decades. Until recently, however, melatonin had not been tested as a protective agent against exocrine pancreatic tumors. This cancer type is highly aggressive and 5 year survival rate in individuals with pancreatic cancer is very low. Recent studies with melatonin indicate it may have utility in the treatment of these otherwise almost untreatable pancreatic cancers. The discovery of melatonin in plants has also opened a vast new field of research which is rapidly being exploited although the specific functions(s) of melatonin in plant organs remains enigmatic. Finally, the described application of melatonin's use as a chemical reductant in industry could well serve as a stimulus to further define the utility of this versatile molecule in new industrial applications....

Read abstract  Full text PDF

Journal Article 2011; 32(5): 588-606 PubMed PMID: 22167135 Citation  Keywords:  Animals, Antioxidants:therapeutic use, Chronobiology Phenomena:drug effects, Circadian Rhythm:drug effects, Cytoprotection:drug effects, Humans, Melatonin:therapeutic use, Obesity:drug therapy, Sleep Wake Disorders:drug therapy,.   

: From a physiological perspective the sleep-wake cycle can be envisioned as a sequence of three physiological states (wakefulness, non-rapid eye movement, NREM, sleep and REM sleep) which are defined by a particular neuroendocrine-immune profile regulating the metabolic balance, body weight and inflammatory responses. Sleep deprivation and circadian disruption in contemporary "24/7 Society" lead to the predominance of pro-orexic and proinflammatory mechanisms that contribute to a pandemic metabolic syndrome (MS) including obesity, diabetes and atherosclerotic disease. Thus, a successful management of MS may require a drug that besides antagonizing the trigger factors of MS could also correct a disturbed sleep-wake rhythm. This review deals with the analysis of the therapeutic validity of melatonin in MS. Melatonin is an effective chronobiotic agent changing the phase and amplitude of the sleep/wake rhythm and having cytoprotective and immunomodulatory properties useful to prevent a number of MS sequels. Several studies support that melatonin can prevent hyperadiposity in animal models of obesity. Melatonin at a low dose (2-5 mg/day) has been used for improving sleep in patients with insomnia and circadian rhythm sleep disorders. More recently, attention has been focused on the development of potent melatonin analogs with prolonged effects (ramelteon, agomelatine, tasimelteon, TK 301). In clinical trials these analogs were employed in doses considerably higher than those usually employed for melatonin. In view that the relative potencies of the analogs are higher than that of the natural compound, clinical trials employing melatonin doses in the range of 50-100 mg/day are needed to assess its therapeutic value in MS....

Read abstract  Full text PDF

Journal Article 2010; 31(Suppl 1): 1-42 PubMed PMID: 20881933 Citation  Keywords:  Antineoplastic Agents:therapeutic use, Antioxidants:therapeutic use, Drug Synergism, Humans, Melatonin:therapeutic use, Neoplasms:drug therapy, Retrospective Studies, Vitamins:therapeutic use,.   

AIMS: the aim of the Di Bella Method (DBM) is to try to overcome the high toxicity level and the limited efficacy of the current medical treatments for cancer.

METHOD: using Melatonin, Retinoids, and vitamins E, D3, and C, components of the extracellular matrix, the DBM reinforces those means that Physiology considers essential for life. Acting together, these differentiating molecules also have an antiangiogenic and antiproliferative effect. Cabergoline and/or Bromocriptin negatively regulate Prolactin, the ubiquitary mitogenic hormone. This effect is reinforced by Somatostatin and/or its analogues by negatively regulating highly mitogenic molecules such as GH and GH-dependent growth factors.

RESULTS: the preliminary results are reported of a retrospective observational study on 553 patients treated with the DBM. These data show that the DBM achieved an evident improvement in the quality of life and a considerable increase in the mean survival rates for every disease and stage with respect to the data available in the literature relative to chemotherapy and/or monoclonal antibodies. The result was achieved without any of the known significant toxic effects of chemotherapy and (albeit to a lesser extent with respect to chemotherapy) of monoclonal antibodies. The invalidating causes which removed all scientific credibility from the DBM experiments carried out in Italy in 1998 are also reported.

CONCLUSIONS: I considered it of use to inform the scientific community of the rationale, the mechanism of action, the scientific basis and clinical findings of the DBM in order to encourage interest in the prospects opened up by the DBM through innovative formulations of the vitamins and Melatonin and the use of biological molecules with a high degree of antitumoural efficacy and low toxicity such as Somatostatin and its analogues....

Read abstract

Journal Article 2010; 31(3): 348-352 PubMed PMID: 20588238 Citation  Keywords:  Action Potentials:drug effects, Animals, Antioxidants:therapeutic use, Brain Ischemia:prevention & control, Female, Hippocampus:drug effects, In Vitro Techniques, Indoles:therapeutic use, Lactation, Pregnancy, Pregnancy Complications, Cardiovascular:drug .   

OBJECTIVE: Damage to the developing brain may be caused by maternal environment, nutritional deficiencies, failure of protective mechanisms, etc. Further, the developing brain may be damaged by intrauterine ischemia or by ischemia in newborns complicated by perinatal asphyxia. There is an effort to find agents with neuroprotective effect on the developing brain. The aim was to study the effect of the new pyridoindole antioxidant SMe1EC2 on the resistance of offspring hippocampus exposed to ischemia in vitro after treatment of mothers.

MATERIALS AND METHODS: The electrically evoked responses were determined by extracellular recording from offspring hippocampal slices. The effect of oral treatment of rats with SMe1EC2 over 18 consecutive days, from day 15 of gestation to day 10 post partum (PP) was analyzed in the model of ischemia in vitro measured on the hippocampus of 21-day-old pups, with focus on neuronal function recovery in reoxygenation.

RESULTS: Increased recovery of neuronal response was found at the end of 20-min reoxygenation in offspring hippocampal slices exposed to 10-min hypoxia/hypoglycemia from rats whose mothers were treated with the dose of 50 and 250 mg/kg of SMe1EC2, compared to control offspring slices (mothers received vehicle over the same time).

CONCLUSIONS: The increased offspring hippocampus resistance to hypoxia/hypoglycemia due to 18-day maternal treatment with SMe1EC2 might have been obtained via the transplacental way as well as in the neonatal period via breast milk, skin and saliva. The manifested neuroprotective effect of SMe1EC2 on the developing brain might find exploitation during risk pregnancy and delivery....

Read abstract  Full text PDF

Case Reports 2009; 30(4): 437-449 PubMed PMID: 20010503 Citation  Keywords:  Antioxidants:therapeutic use, Drug Therapy, Combination, Humans, Infant, Magnetic Resonance Imaging, Male, Melatonin:therapeutic use, Neuroblastoma:diagnostic imaging, Positron-Emission Tomography, Remission Induction, Retinoids:therapeutic use, Retroperi.   

OBJECTIVES: The combined use (MDB) of Somatostatin, Melatonin, Retinoids, Vitamins E, C, and D3, with Calcium, Chondroitin sulfate, and microdoses of Cyclophosphamide in a seven-month old baby affected by a voluminous retroperitoneal neuroblastoma measuring 4 x 8 cm produced a 50% objective response in six months, an almost total response in one year and a complete response at 14 months, with cure and absence of disease for over ten years.

RESULTS: This paper discusses the rationale and the molecular mechanisms of action of the treatment which has a differentiating, apoptotic and antiproliferative effect, preserving and enhancing both the trophism and functionality of organs and tissues, and the neuroimmunoendocrine and antiblastic homeostasis. This result is in agreement with the positive results already published on the use of the MDB in lymphoproliferative diseases, in stage III and IV lung cancer, in breast cancer and in cancers of the upper aerodigestive epithelia. Without the need for hospitalisation and with no toxicity, the MDB rapidly reduced and then eliminated the voluminous tumoral mass, allowing a normal quality of life and a perfectly normal psychophysical development.

CONCLUSIONS: We believe it is of use to report this case in order to invite greater interest in the oncological possibilities offered by the immunoneuroendocrine and biological-receptorial properties of the MDB treatment....

Read abstract  Full text PDF

Journal Article 2008; 29(6): 902-910 PubMed PMID: 19112401 Citation  Keywords:  Adult, Age Factors, Analysis of Variance, Anti-Inflammatory Agents:therapeutic use, Antibodies, Bacterial:blood, Antioxidants:therapeutic use, Bacterial Translocation:immunology, Diet Therapy, Enterobacteriaceae:immunology, Fatigue Syndrome, Chronic:blood.   

BACKGROUND: There is now evidence that an increased translocation of LPS from gram negative bacteria with subsequent gut-derived inflammation, i.e. induction of systemic inflammation and oxidative & nitrosative stress (IO&NS), is a new pathway in chronic fatigue syndrome (CFS).

METHODS: The present study examines the serum concentrations of IgA and IgM to LPS of gram-negative enterobacteria, i.e. Hafnia Alvei; Pseudomonas Aeruginosa, Morganella Morganii, Pseudomonas Putida, Citrobacter Koseri, and Klebsielle Pneumoniae in CFS patients both before and after intake of natural anti-inflammatory and anti-oxidative substances (NAIOSs), such as glutamine, N-acetyl cysteine and zinc, in conjunction with a leaky gut diet during 10-14 months. We measured the above immune variables as well as the Fibromyalgia and Chronic Fatigue Syndrome Rating Scale in 41 patients with CFS before and 10-14 months after intake of NAIOSs.

RESULTS: Subchronic intake of those NAIOSs significantly attenuates the initially increased IgA and IgM responses to LPS of gram negative bacteria. Up to 24 patients showed a significant clinical improvement or remission 10-14 months after intake of NAIOSs. A good clinical response is significantly predicted by attenuated IgA and IgM responses to LPS, the younger age of the patients, and a shorter duration of illness (< 5 years).

DISCUSSION: The results show that normalization of the IgA and IgM responses to translocated LPS may predict clinical outcome in CFS. The results support the view that a weakened tight junction barrier with subsequent gut-derived inflammation is a novel pathway in CFS and that it is a new target for drug development in CFS. Meanwhile, CFS patients with leaky gut can be treated with specific NAIOSs and a leaky gut diet....

Read abstract  Full text PDF